Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer

Related Experiment Video

Updated: Jun 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sumanta Kumar Pal, Oliver Sartor

    Maturitas
    |November 25, 2010
    PubMed

    Insights

    Abiraterone, a CYP17 inhibitor, demonstrated a survival benefit for metastatic castration-resistant prostate cancer (mCRPC) patients post-docetaxel therapy. This finding adds a new option to the prostate cancer treatment landscape.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • A phase III study presented at the 2010 European Society for Medical Oncology (ESMO) meeting evaluated abiraterone, a CYP17 inhibitor.
    • The study focused on patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel therapy.

    Discussion:

    • Abiraterone demonstrated a significant survival advantage compared to placebo in this patient population.
    • This result positions abiraterone as a valuable therapeutic option in the evolving landscape of prostate cancer treatment.
    • The findings emerge alongside other recent advancements, including cabazitaxel and sipuleucel-T.

    Key Insights:

    • Abiraterone offers a survival benefit for mCRPC patients progressing after docetaxel.
    • The agent targets CYP17, a key enzyme in androgen biosynthesis.
    • Clinical data supports abiraterone's efficacy in a heavily pre-treated mCRPC population.

    Outlook:

    • Ongoing trials are investigating abiraterone in earlier stages of prostate cancer, including pre-docetaxel mCRPC.
    • Further research is exploring combinations of abiraterone with radiation therapy and its use as neoadjuvant therapy for localized disease.
    • Determining the optimal placement of abiraterone within the current treatment paradigm is a key challenge.

    More Related Videos

    Serum and Plasma Copy Number Detection Using Real-time PCR09:21

    Serum and Plasma Copy Number Detection Using Real-time PCR

    Published on: December 15, 2017

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...